Shares of Shasun Pharmaceuticals were locked in upper circuit for second straight day after it rose 10 per cent to Rs 165, extending its three-day gain to nearly 30 per cent.
According to the bulk deal data of NSE, Morgan Stanley Asia (Singapore) PTE bought 402,545 shares for Rs 146.86 per equity share.
On May 5, Shasun had announced that it had acquired the global rights from ScolrPharma to develop and commercialize Ibuprofen 12-hour extended release OTC tablets as well as the associated controlled release technology along with global rights of Nuprin trademark.
Shares of Shasun Pharmaceuticals were locked in upper circuit for second straight day after it rose 10 per cent to Rs 165, extending its three-day gain to nearly 30 per cent.
According to the bulk deal data of NSE, Morgan Stanley Asia (Singapore) PTE bought 402,545 shares for Rs 146.86 per equity share.
On May 5, Shasun had announced that it had acquired the global rights from ScolrPharma to develop and commercialize Ibuprofen 12-hour extended release OTC tablets as well as the associated controlled release technology along with global rights of Nuprin trademark.
Shares of Shasun Pharmaceuticals were locked in upper circuit for second straight day after it rose 10 per cent to Rs 165, extending its three-day gain to nearly 30 per cent.
According to the bulk deal data of NSE, Morgan Stanley Asia (Singapore) PTE bought 402,545 shares for Rs 146.86 per equity share.
On May 5, Shasun had announced that it had acquired the global rights from ScolrPharma to develop and commercialize Ibuprofen 12-hour extended release OTC tablets as well as the associated controlled release technology along with global rights of Nuprin trademark.
Sign Up with Google
RECOMMENDED FOR YOU
POPULAR